B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity - Yonesaka, Kimio; Haratani, Koji; Takamura, Shiki; Sakai, Hitomi; Kato, Ryoji; Takegawa, Naoki; Takahama, Takayuki; Tanaka, Kaoru; Hayashi, Hidetoshi; Takeda, Masayuki; Kato, Sigeki; Maenishi, Osamu; et al. (Clinical cancer research, 2018)
Keywords: Aged; Aged, 80 and over; Animals; Anticancer properties; Antineoplastic Agents, Immunological - pharmacology; Antineoplastic Agents, Immunological - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Antitumor activity; Apoptosis; B7 antigen; B7 Antigens - metabolism; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - metabolism; Biomarkers, Tumor; Blocking antibodies; Cancer; CD8 antigen; Cell survival; Cytotoxicity; Disease Models, Animal; Drug Resistance, Neoplasm; Effectiveness; Experimental design; Female; Flow cytometry; Humans; Immune checkpoint; Immunity; Immunomodulation; Immunosurveillance; Immunotherapy; Lung cancer; Lymphocytes; Lymphocytes T; Male; Mice; Middle Aged; Molecular chains; Molecular Targeted Therapy; Mutation; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - pathology; Neoplasms - therapy; Non-small cell lung carcinoma; PD-1 protein; PD-L1 protein; Prognosis; T-Lymphocytes, Cytotoxic - immunology; T-Lymphocytes, Cytotoxic - metabolism; Therapy; Treatment Outcome; Tumor cells; Tumor-infiltrating lymphocytes; Tumors; Xenograft Model Antitumor Assays